BioSpace News Archive

Imagin Medical (CSE:IME) (OTCQB:IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reported financial results for the three months ended June 30, 2020

Gilead’s Investigational Antiviral Veklury ® (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19 -- Expands Previous Authorization of Veklury to Treat Hospitalized Patients with COVID-19 Regardless of Oxygen Status -- FOSTER CITY, Calif.--( BUSINESS WIRE )-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) expanded

Mylan N.V. (NASDAQ: MYL) today announced that its U.S.-based Mylan Institutional LLC business is conducting a voluntary nationwide recall to the hospital/clinic level of four lots of Amiodarone HCl Injection, USP 450 mg/9 mL, packaged in cartons of 10 single-dose 9 mL vials and Tranexamic Acid Injection,

Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announces that, further to its July 28, 2020 press release, it continues to rely on blanket exemptions issued by provincial securities commissions due to the COVID-19 outbreak that permit the Company to extend the filing deadline of its annual financial statements

XORTX Therapeutics Inc. (CSE : XRX) (OTCQB : XRTXF) (FRANKFURT : ANU1) (the “Company” or “XORTX”) a late clinical stage pharmaceutical development company focused on kidney disease, is pleased announce that Ian Klassen will join the XORTX board of directors effective immediately.

Discoveries from the Benaroya Research Institute at Virginia Mason (BRI) have identified a new cellular protection pathway that targets a common vulnerability in several different pandemic viruses, and collaborators at Case Western Reserve University, Boston University School of Medicine and MRIGlobal have shown that this pathway can protect cells from infection by Ebola virus and coronaviruses

JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has chosen its bottling and labeling partner to support upcoming clinical trials

Braingrid Limited is pleased to announce the appointment of Mr. Andrew Parks as the Company’s Interim Chief Executive Officer, who will lead a review of the Company’s business and potential strategic alternatives.

Atrium Health has passed a significant milestone in its Million Mask Initiative, announcing today it has now distributed more than 1 million free masks in the Charlotte regio

HYCOR Biomedical, a leading manufacturer of in vitro diagnostic products for allergy testing, and Changsha Haike Biotechnology Co., Ltd., its Chinese manufacturing partner, announced registration from Hunan Medical Products Administration (HMPA) for the ALLEOS 2000 allergy testing system on August 4, 2020 . “The registra